Aratana Therapeutics Granted Full License for AT-004 by USDA
Aratana's biologics portfolio also includes, AT-005, a canine lymphoma monoclonal antibody targeting CD52 as an aid in the treatment of T-cell lymphoma in dogs, which received a conditional license from the USDA in January 2014. Aratana also submitted …
Read more on PR Newswire (press release)
February 25, 2015